ReviewFrontiers in pharmacology2026
From toxicity to signal: positioning symptom clusters as pharmacodynamic indicators in ICI therapy.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICIs) have enhanced the treatment of cancer, but their clinical effect is usually limited by immune-related adverse events (irAEs). Currently, it is recognized that these toxicities are not merely common side effects. Rather, they are a set of complicated symptoms caused by different cytokine networks with different occurrences, progress and affected organ systems. Therefore, We propose that symptom assessment should not be limited to safety monitoring. Symptom complexes should be regarded as dynamic and easily accessible pharmacodynamic indicators of ICI effects. By analyzing certain symptom arrangements (such as IL-6 induced colitis), doctors can determine the main immune pathways affected. This change in view converts the management of irAE from an empirical and broad-spectrum immunosuppression to a strategy based on mechanism, thus achieving the separation of toxicity control from antitumor efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.